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Abstract: Metastatic thymic carcinoma is an aggressive neoplasm
for which multimodal therapies are often ineffective. We describe
here a heavily pretreated patient with advanced thymic carcinoma
responsive to multikinases inhibitor BAY 43-9006 (Sorafenib). Of
note, a hitherto unreported c-kitmissense mutation on exon 17 (D820E)
identified in tumor cells seems to explain the clinical response and
highlight the key role of molecular analysis in predicting efficacy of
targeted therapies even in thymic neoplasms.
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CASE REPORT
A 46-year-old man was referred to our institution in August
2001 after the assessment of a 9 cm mass in the upper anterior
mediastinum extending to the sternum for which he under-
went surgical resection. Surgery was not radical because of
pericardial involvement and the presence of liver metasta-
sis in the left lobe. The tumor consisted of a proliferation
of relatively monomorphic, rounded-to-spindled cells with
prominent eosinophilic nucleoli (Figure 1A), showing ne-
crotic foci and high mitotic rate (35  10 high-power-
fields). Tumor cells immunostained with cytokeratins,
CD5, c-kit/CD117 (Figure 1B), but not for chromogranin,
synaptophysin, and CD56. A diagnosis of undifferentiated
thymic carcinoma with extensive capsular invasion (pT3,
N2, M1) was made.
The patient then was treated with one course of PE
(Cisplatin 70 mg/m2, day 1 and Etoposide 120 mg/m2, q3w)
and five courses of PEI (Cisplatin 20 mg/m2, Etoposide 75
mg/m2, and Ifosfamide 1200 mg/m2, days 1–4, q3w) with
partial response in liver metastases and subsequent total
excision of left hepatic lobe. He was disease-free for 1 year
when pulmonary and hepatic metastases were detected.
Radiofrequency ablation of the hepatic lesion followed
by three additional PEI courses were performed with partial
remission and subsequent complete excision of pulmonary
metastases. In April 2004, computed tomography (CT) de-
tected multiple lung and liver nodules and four cycles of
chemotherapy with doxorubicin and ifosfamide (Doxorubicin
35 mg/m2 and Ifosfamide 3000 mg/m2, days 1–3, q3w) were
given achieving clinical partial response. In January 2005, the
patient had disease progression with increase of liver and
lungs metastases. In the absence of any standardized subse-
quent-line chemotherapy, an empiric treatment with long-
acting release octreotide (20 mg per month, subcutaneously)
was performed. Intracranial tumor progression occurred and a
cerebral necrotic lesion was surgically removed. Liver and
lung metastases were stable and octreotide treatment was
stopped. Further restaging showed multiple bilateral lung and
liver metastases, and a parietal intracranial metastasis.
In the meantime, tumor cells were investigated by
immunohistochemical expression of epidermal growth factor
receptor (EGFR), vascular endothelial growth factor (VEGF),
c-met, and platelet-derived growth factor receptor (PDGFR)-
alpha and -beta without evidence of immunoreactivity. Most
important, molecular analysis by polymerase chain reaction-
based direct sequencing showed a missense mutation in c-kit
exon 17 (D820E) (Figure 1C). No alterations were observed
in the other tested genes: c-kit exons 9, 11, 13, and 14,
PDGFR-alpha exons 12, 14, 17, PDGFR-beta exons 12, 14,
18, 19, 20, c-met exons 14, 17, 18, 19, EGFR exons 18, 19,
20, 21, and BRAF exon 15.
The finding of this mutational event lead us to start a
targeted therapy with BAY 43-9006 (sorafenib, Nexavar,
Bayer Pharmaceutical), an oral inhibitor acting against sev-
eral tyrosine (VEGFR, PDGFR, c-kit), and serine/threonine
(B-RAF, p38) kinases.
The institutional Ethical Committee of our Hospital
approved the treatment and the patient gave written informed
consent. Treatment with two 100 mg capsules of sorafenib
twice daily was started in October 2007.
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After 8 weeks of this treatment, a partial response was
detected by CT scan according to World Health Organization
criteria. Before sorafenib therapy, multiple metastases were
present in liver, lungs (Figures 2A, B), and brain. After
treatment with sorafenib, a clinical response was confirmed in
all metastatic sites (Figures 2C, D). Sorafenib was well
tolerated and improvement in both symptoms control and
performance status was registered. Adverse events consisted of
a grade 2 of skin desquamation and pruritus, grade 1 diarrhea,
and grade 1 fatigue. Skin toxicity was resolved discontinuing
sorafenib for 1 week every 4 weeks of treatment. No other
toxicities were noted. After 15 months, this heavily pretreated
patient (followed-up with CT scans every 3 months) is still in
partial response continuously receiving sorafenib.
DISCUSSION
When metastatic spread from thymic carcinomas oc-
curs, multimodal treatment basically represents the only ef-
fective therapy.1 Most regimens include cisplatin and the best
results have been reported with the PE, cyclophosphamide,
doxorubicin, cisplatin (PAC) and cisplatin doxorubicin, vin-
cristine, cyclophosphamide (ADOC) regimens.1 The overall
response rate has ranged from 30 to 90% and the median
duration of response has ranged from 12 to 36 months.1
To date, there are no established therapeutic protocols
for advanced, metastatic thymomas or thymic carcinomas,
mainly due to the rarity of the disease. Among anecdotic
experiences with targeted therapy, somatostatin analogues
(namely octreotide) in advanced thymomas have reported a
response rate of 32% and 2-year survival of 76%.1 Interest-
ingly, previous studies demonstrated that thymic carcinomas,
but not thymomas, strongly stain with c-kit,2 a type III
receptor tyrosine kinase (RTK) consistently overexpressed by
gastrointestinal stromal tumors (GIST) in which the relevant
c-kit gene is mutated in up to 90% of cases.
By contrast, thymomas, but not thymic carcinomas,
significantly express the EGFR,2 another RTK widely ex-
pressed in carcinomas from different sites and mutated in 10
to 30% of pulmonary adenocarcinomas.
Based on these preliminary observations, partial re-
sponses has been reported in single case reports using ima-
tinib mesylate, a type III RTK small molecule inhibitor, in a
thymic carcinoma showing a c-kit in-frame deletion in exon
11 (V560del),3 and cetuximab, a monoclonal humanized
antibody against EGFR, in an advanced B2-type thymoma
strongly expressing EGFR.4 More recently, a partial tumor
size resolution was observed in a metastatic B2-type thy-
moma using dasatinib, a multitargeted small molecule inhib-
itor of several RTK, as Bcr-Abl, kinases along Src family,
PDGFRs, and c-kit.5
Preclinical and clinical activity with sorafenib, an oral
multikinase inhibitor with effects on tumor cell proliferation
FIGURE 1. Undifferentiated thymic
carcinoma consisting of a mono-
morphic proliferation of rounded-to-
spindled shaped cells with promi-
nent nucleoli and mitotic rate (A)
strongly expressing c-kit/CD117 (B)
and harboring a missense mutation
at c-kit exon 17 (D820E) (electro-
pherogram, see arrows C).
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and tumor angiogenesis, was well-demonstrated mainly in a
small subset of renal cell and hepatocellular carcinomas,
although no clear-cut molecular explanations on the exact
mechanisms of antitumor activity have been so far reported.
So far, only a recent case report by Li et al.6 evidenced a
clinical response with sorafenib in a 46-year-old man with
a thymic carcinoma expressing c-kit (CD117) and VEGF,
but without clear-cut molecular explanation for such a
clinical result.
In the current case, we demonstrated the presence of a
hitherto unreported gain-of-function constitutive somatic mu-
tation involving the proto-oncogene c-kit in tumor cells of a
metastatic, chemoresistant thymic carcinoma. The patient had
a prompt and prolonged partial response using sorafenib, in
absence of significant toxicity.
Of note, an identical somatic missense mutation
(D820E) involving the activation loop of the c-kit tyrosine
kinase (TK) was previously identified only in a small subset
of GIST resistant to imatinib mesylate.7 Exactly in GIST
harboring imatinib-resistant c-kit mutations involving gate-
keeper and kinase catalytic domains, sorafenib seems partic-
ularly effective, these molecular findings convincingly ex-
plaining the clinical response obtained in our patient.
Unfortunately, we did not observe mutations in c-kit,
PDGFR (-alpha and -beta), and EGFR in a series of primary
thymic neoplasms including 10 thymic carcinomas and 20
thymomas (5 type A, 4 type AB, 2 type B1, 4 type B2, and
5 type B3) (Rossi G., personal not published observations
June 2008). Our results are in agreement with recent studies,
confirming that c-kit, PDGFRs, and EGFR mutations in
thymic tumors are extremely rare.8,9 Although sporadic, these
genetic alterations represent critical molecular events in tu-
mor growth of thymic epithelial neoplasms and can predict
responsiveness with TK inhibitors, as well-exemplified in
GIST. Given the lack of effective therapy for unresectable or
metastatic chemoresistant thymic tumors and the dismal-
related prognosis, knowledge of the role of “drugable” recep-
tor kinases possibly through molecular screening for activat-
ing mutations may be helpful in identifying patients that
could benefit from sorafenib or other targeted therapies.
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FIGURE 2. Computed tomogra-
phy (CT) scan studies of the lungs
(A, B) before sorafenib therapy
(October 2007) showing multiple
pulmonary metastases. Absence of
contrast enhancement or disappear-
ance of pulmonary lesions (C, D) con-
firmed partial response to sorafenib
therapy (December 2007).
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